News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genovis Evaluates New Technology for Early Diagnosis of Cardiovascular Disease



8/14/2013 8:35:05 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Genovis signed an agreement with Repiratorius to test and evaluate RESP-3000 as a new biomarker for early diagnosis of cardiovascular disease using PET-Imaging. Genovis is coordinating the work, but GeccoDots AB, Genovis’ wholly owned subsidiary, will conduct the final evaluation. Work will begin immediately and the evaluation is expected to be completed in late 2013 or early 2014. The agreement includes the option for Genovis to acquire technology and patents relating to RESP-3000 in preclinical applications and Genovis intends to initiate negotiations for an acquisition if the tests show favorable results.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Genovis
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES